Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia

Current Medical Research and Opinion

Volumn 27, Issue 1, 2011, Pages 115-122

  Ascher Svanum, Haya ^a   Stensland, Michael D ^b   Peng, Xiaomei ^a   Faries, Douglas E ^a   Stauffer, Virginia L ^a   Osuntokun, Olawale O ^a   Kane, John M ^c  

^a ELI LILLY AND COMPANY   (United States)

^b Agile Outcomes Research Inc   (United States)

^c ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

Aripiprazole; Cost effectiveness analysis; Olanzapine; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE;

ADULT; AGE DISTRIBUTION; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; ORTHOSTATIC HYPOTENSION; PARKINSONISM; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEX RATIO; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT DURATION; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PIPERAZINES; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 78650329688     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.537594     Document Type: Article

References (31)

1. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56
2. Saha S, Chant D, Welham J, et al. A systematic review of the prevalence of schizophrenia. PLoS Med 2005;2:e141
3. Wu EQ, Birnbaum HG, Shi L, et al. The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005;66:1122-9
4. Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health 2009;12:536-43
5. Marwaha S, Johnson S. Schizophrenia and employment - a review. Soc Psychiatry Psychiatr Epidemiol 2004;39:337-49
6. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009;166:152-63
7. Leucht S, Kissling W, Davis JM. Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 2009;39:1591-602
8. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
9. Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006;163:2080-89
10. Furiak NM, Ascher-Svanum H, Klein RW, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff Resour Alloc 2009;7:4
11. Edwards NC, Pesa J, Meletiche DM, et al. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Curr Med Res Opin 2008;24:3341-55
12. Bettinger TL, Shuler G, Jones DR, et al. Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics. Ann Pharmacother 2007;41:201-7
13. Kane JM, Osuntokun O, Kryzhanovskaya LA, et al. A 28-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia. J Clin Psychiatry 2009;70:572-81
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR Fourth Edition. American Psychiatric Publishing, Inc. 2000
15. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndome Scale (PANSS) User's Manual. North Tonawanda, NY: Multi-Health Systems, Inc., 2000
16. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine, 1st edn. USA: Oxford University Press, 1996
17. Kane JM, Kim E, Kan HJ, et al. Comparative utility of aripiprazole and halo-peridol in schizophrenia: post hoc analysis of two 52-week, randomized, controlled trials. Appl Health Econ Health Policy 2009;7:109-19
18. Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2004; 71:155-65
19. Lenert LA, Sturley AP, Rapaport MH, et al. Corrigendum to public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores. Schizophr Res 2005;80:135-6
20. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
21. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154:672-6
22. National Institute of Mental Health. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD: US National Institute of Health, 1976:534-7
23. Mohr PE, Cheng CM, Claxton K, et al. The heterogeneity of schizophrenia in disease states. Schizophr Res 2004;71:83-95
24. Mahmoud RA, Engelhart LM, Janagap CC, et al. Risperidone versus conventional antipsychotics for schizophrenia and schizoaffective disorder: symptoms, quality of life and resource use under customary clinical care. Clin Drug Investig 2004;24:275-86
25. Analysource Data. AWP cost of antipsychotics. Available at: http://www.analysource.com [Last accessed 31 March 2008]
26. Obenchain RL, Robinson RL, Swindle RW. Cost-effectiveness inferences from bootstrap quadrant confidence levels: three degrees of dominance. J Biopharm Stat 2005;15:419-36
27. Meltzer DO, Basu A, Meltzer HY. Comparative effectiveness research for antipsychotic medications: how much is enough? Health Aff 2009;28: w794-808
28. Polsky D, Doshi JA, Bauer MS, et al. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 2006;163:2047-56
29. Fleischhacker WW, McQuade RD, Marcus RN, et al. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry 2009;65:510-17
30. Komossa K, Rummel-Kluge C, Schmid F, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2009;CD00656922
31. McQuade RD, Stock E, Marcus R, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl. 18):47-56